Modular Medical Faces Challenges Amid FDA Approval and Funding
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Modular Medical Inc. (NASDAQ: MODD) is a development-stage medical device company headquartered in San Diego, California. Founded by Paul M. DiPerna, it develops insulin delivery technologies aimed at simplifying diabetes management. On June 26, 2025, the company’s shares closed at $0.75, a decrease of 7.41% from the previous session, trading 1,001,701 shares compared to an average volume of 1,701.
| Ticker | Exchange | Price (06/26/2025) | Change | Volume | Avg. Volume |
|---|---|---|---|---|---|
| MODD | NASDAQ | $0.75 | -7.41% | 1,001,701 | 1,701 |
Corporate Structure
Modular Medical employs between 11 and 50 staff, drawing expertise from medical device engineering, regulatory affairs, and commercial operations. CEO Jeb Besser leads a senior team that includes inventor Paul DiPerna, whose previous venture, Tandem Diabetes Care, developed the t:slim insulin pump. The company maintains research and development facilities in San Diego and has established a "Talent Bench" initiative to identify potential hiring needs.
Recent Developments and News
In January 2024, Modular Medical announced a $12 million private placement, selling units at $1.92 per unit—each unit comprised of two common shares and one warrant—expected to close on or about March 25, 2024. Proceeds will support supply chain optimization and margin improvement for the MODD1 patch pump and advance preparations for an FDA submission of a tubeless version planned for the third quarter of 2025.
On September 22, 2023, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the MODD1, a 90-day patch pump featuring proprietary microfluidics technology, a 300-unit reservoir, and smartphone monitoring capability without an external controller.
The U.S. Securities and Exchange Commission (SEC) declared effective Modular Medical’s Form S-3 registration statement on May 22, 2025, enabling additional capital raising. Subsequently, on May 28, 2025, the company filed a Form 8-K (items 5.02, 8.01, and 9.01), which typically addresses executive appointments and material events, though specific details were not disclosed in the summary filing.
Between June 20 and June 23, 2025, Modular Medical participated in the American Diabetes Association’s 85th Scientific Sessions in Chicago. On June 22, 2025, poster #783-P detailed an exploratory study in diet-induced obese mice comparing continuous pump-delivered exenatide with intermittent semaglutide dosing, evaluating the potential of pump-based GLP-1R agonist therapy.
Financial and Strategic Analysis
As a development-stage company, Modular Medical has yet to generate significant product revenues. The June 20, 2025 10-K filing (Acc-no: 0001213900-25-055793) provides fiscal-year financial statements, including metrics on research and development expenditures, operating cash flow, and net loss. Management's discussion highlights investments in manufacturing scale-up and clinical activities, balanced by cash on hand from 2024 and 2025 financing rounds.
The effective S-3 registration and previous placements indicate a strategy to maintain liquidity for product commercialization, regulatory submissions, and market launch. Continued funding will be essential to finance margin improvements on the MODD1, support the planned tubeless pump submission in Q3 2025, and pursue CE marking for European distribution.
Market Position and Industry Context
Modular Medical operates in a market with significant competition from established insulin pump manufacturers, including Medtronic, Insulet, and Tandem Diabetes Care. Its 90-day patch pump seeks to differentiate based on simplicity, cost-effectiveness, and user experience by eliminating external controllers and employing a disposable single-use battery. The exploration into pump-based GLP-1R agonist delivery could potentially expand therapy applications beyond insulin and align with broader trends toward integrated diabetes care solutions.
tl;dr
- Stock closed at $0.75 on June 26, 2025, down 7.41% on record volume.
- January 2024 private placement raised $12 million; FDA cleared the MODD1 patch pump on September 22, 2023.
- SEC approved S-3 registration on May 22, 2025; Form 8-K filed May 28, 2025.
- Presented GLP-1R agonist pump study at ADA Scientific Sessions on June 22, 2025.
- Plans include a Q3 2025 FDA submission for a tubeless insulin patch pump and pursuit of CE marking.